U.S. Markets closed

Ovid Therapeutics Inc. (OVID)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7100+0.1300 (+5.04%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5800
Open2.5700
Bid2.6900 x 4000
Ask2.7200 x 1000
Day's Range2.5204 - 2.7400
52 Week Range1.8000 - 9.4000
Volume2,509,981
Avg. Volume1,705,442
Market Cap171.909M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)-1.3880
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
  • Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?
    Simply Wall St.

    Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

    We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

  • Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index
    GlobeNewswire

    Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index

    NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology IndexSM Fund. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com/Index/Overview/NBI.About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The Company is developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited, which is expected to initiate its pivotal clinical trials in 2021 for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). OVID is evaluating the results of the NEPTUNE trial of OV101 (gaboxadol) for the treatment of Angelman syndrome  and Fragile X syndrome. For more information on Ovid, please visit www.ovidrx.com.ContactsInvestors and Media: Ovid Therapeutics Inc. Investor Relations & Public Relations irpr@ovidrx.comORInvestors: Argot Partners Maeve Conneighton/Dawn Schottlandt 212-600-1902 ovid@argotpartners.comMedia: Dan Budwick 1AB dan@1abmedia.com

  • Is OVID A Good Stock To Buy Right Now?
    Insider Monkey

    Is OVID A Good Stock To Buy Right Now?

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]